Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy
Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy
复制标题
DOI：
10.1007/s12013-015-0564-1
复制
发表时间：
2015-02
影响因子：
2.6
通讯作者：
Peipei Zhang;Zhanyu Zhou
中科院分区：
文献类型：
--
作者：
Peipei Zhang;Zhanyu Zhou
积累的证据支持糖尿病视网膜病变是由微血管和神经胶质区室的功能和结构改变引起的。在这里，我们探讨了贝伐珠单抗和 NGF 联合使用对预防糖尿病视网膜病变的有益效果。 STZ 诱导的糖尿病大鼠被随机分为三组：假手术组、贝伐单抗组和联合组（贝伐单抗 + NGF）。治疗结束时，通过 FITC-葡聚糖评估血管异常。还通过实时 PCR 和蛋白质印迹研究了炎症和血管生成因子。我们的结果表明，贝伐珠单抗及其联合用药均可显着降低 6 周糖尿病大鼠的异常血管通透性并限制炎症和血管生成。然而，与单独使用贝伐珠单抗相比，该组合对 12 周糖尿病大鼠具有更好的预防效果。我们的研究结果表明，贝伐珠单抗与 NGF 联合可能成为预防性干预糖尿病视网膜病变的新方法。
Accumulated evidences support diabetic retinopathy is caused by functional and structural alterations in both the microvascular and neuroglial compartments. Here, we explored any beneficial effects of combination of Bevacizumab and NGF to prevent diabetic retinopathy. STZ-induced diabetic rats were randomly grouped into three groups: sham, Bevacizumab and combination group (Bevacizumab + NGF). End of the treatment, vascular abnormality was evaluated by FITC-dextran. Inflammation and angiogenesis factors were also investigated by real-time PCR and western blot. Our results showed both Bevacizumab and the combination could dramatically reduce abnormal vascular permeability and limit the inflammatory and angiogenesis in 6-week diabetic rats. However, the combination indicated better preventive effects in 12-week diabetic rats compared with Bevacizumab alone. Our findings suggest that the combination of Bevacizumab with NGF may be a new method for the preventive intervention of diabetic retinopathy.